These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 6193701)

  • 21. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
    Fish FA; Gillette PC; Benson DW
    J Am Coll Cardiol; 1991 Aug; 18(2):356-65. PubMed ID: 1906902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of frequent ventricular arrhythmia with encainide: assessment using serial ambulatory electrocardiograms, intracardiac electrophysiologic studies, treadmill exercise tests, and radionuclide cineangiographic studies.
    DiBianco R; Fletcher RD; Cohen AI; Gottdiener JS; Singh SN; Katz RJ; Bates HR; Sauerbrunn B
    Circulation; 1982 Jun; 65(6):1134-47. PubMed ID: 6804110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Encainide: a new antiarrhythmic agent.
    Wehmeyer AE; Thomas RL
    Drug Intell Clin Pharm; 1986 Jan; 20(1):9-13. PubMed ID: 3080301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of encainide on the inducibility of ventricular arrhythmia in normal anesthetized dogs.
    Zeng FD; Nattel S
    J Tongji Med Univ; 1986; 6(1):60-6. PubMed ID: 3086567
    [No Abstract]   [Full Text] [Related]  

  • 25. Sinus node dysfunction and sudden cardiac death following treatment with encainide.
    Lemery R; Talajic M; Nattel S; Theroux P; Roy D
    Pacing Clin Electrophysiol; 1989 Oct; 12(10):1607-12. PubMed ID: 2477816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Encainide and flecainide: are they interchangeable?
    Saini V; Podrid PJ; Slater W; Lown B
    Am Heart J; 1989 Jun; 117(6):1253-8. PubMed ID: 2499169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electrophysiologic and clinical effects of intravenous and oral encainide in accessory atrioventricular pathway.
    Kunze KP; Kuck KH; Schlüter M; Kuch B; Bleifeld W
    Am J Cardiol; 1984 Aug; 54(3):323-9. PubMed ID: 6431796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignant ventricular tachyarrhythmias associated with the use of encainide.
    Winkle RA; Mason JW; Griffin JC; Ross D
    Am Heart J; 1981 Nov; 102(5):857-64. PubMed ID: 6795909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
    Akhtar M; Breithardt G; Camm AJ; Coumel P; Janse MJ; Lazzara R; Myerburg RJ; Schwartz PJ; Waldo AL; Wellens HJ
    Circulation; 1990 Mar; 81(3):1123-7. PubMed ID: 1689621
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety considerations and dosing guidelines for encainide in supraventricular arrhythmias.
    Soyka LF
    Am J Cardiol; 1988 Dec; 62(19):63L-68L. PubMed ID: 3144170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lidocaine (Xylocaine) as an anti-arrhythmic agent.
    Med Lett Drugs Ther; 1971 Jan; 13(1):1-2. PubMed ID: 4104507
    [No Abstract]   [Full Text] [Related]  

  • 32. Encainide and flecainide in children: separating the wheat from the chaff.
    Perry JC; Garson A
    J Am Coll Cardiol; 1991 Aug; 18(2):366-7. PubMed ID: 1906903
    [No Abstract]   [Full Text] [Related]  

  • 33. Dose-response range of encainide for benign and potentially lethal ventricular arrhythmias.
    Morganroth J; Pool P; Miller R; Hsu PH; Lee I; Clark DM
    Am J Cardiol; 1986 Apr; 57(10):769-74. PubMed ID: 3083665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia.
    Kuck KH; Kunze KP; Schlüter M; Duckeck W
    Am J Cardiol; 1988 Dec; 62(19):37L-44L. PubMed ID: 3144166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia.
    Mason JW; Peters FA
    Circulation; 1981 Mar; 63(3):670-5. PubMed ID: 6780234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Noninvasive evaluation of indecainide for serious ventricular tachyarrhythmia.
    Podrid PJ; Hohnloser S; Lown B
    Am J Cardiol; 1988 Apr; 61(10):764-9. PubMed ID: 2451415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs for cardiac arrhythmias: new warning.
    Med Lett Drugs Ther; 1989 May; 31(792):48. PubMed ID: 2497313
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
    Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH
    Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
    Cardiac Arrhythmia Pilot Study (CAPS) Investigators
    Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ventricular arrhythmias in the absence of organic heart disease.
    Sung RJ; Fan W; Huycke EC
    Cardiovasc Clin; 1992; 22(1):149-63. PubMed ID: 1370215
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.